vs

Side-by-side financial comparison of Cheer Holding, Inc. (CHR) and PROCEPT BioRobotics Corp (PRCT). Click either name above to swap in a different company.

PROCEPT BioRobotics Corp is the larger business by last-quarter revenue ($83.1M vs $71.0M, roughly 1.2× Cheer Holding, Inc.). Cheer Holding, Inc. runs the higher net margin — 10.9% vs -38.1%, a 49.0% gap on every dollar of revenue. On growth, PROCEPT BioRobotics Corp posted the faster year-over-year revenue change (20.2% vs -0.1%).

Cheer Holding, Inc. is a diversified holding company primarily operating in the Chinese market, with core business segments covering early childhood education services, mobile lifestyle platforms, digital content offerings, and integrated consumer solutions for households and enterprise partners across multiple demand scenarios.

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

CHR vs PRCT — Head-to-Head

Bigger by revenue
PRCT
PRCT
1.2× larger
PRCT
$83.1M
$71.0M
CHR
Growing faster (revenue YoY)
PRCT
PRCT
+20.3% gap
PRCT
20.2%
-0.1%
CHR
Higher net margin
CHR
CHR
49.0% more per $
CHR
10.9%
-38.1%
PRCT

Income Statement — Q2 FY2025 vs Q1 FY2026

Metric
CHR
CHR
PRCT
PRCT
Revenue
$71.0M
$83.1M
Net Profit
$7.8M
$-31.6M
Gross Margin
70.7%
64.9%
Operating Margin
11.7%
-4.1%
Net Margin
10.9%
-38.1%
Revenue YoY
-0.1%
20.2%
Net Profit YoY
-37.5%
-27.9%
EPS (diluted)
$0.67
$-0.56

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CHR
CHR
PRCT
PRCT
Q1 26
$83.1M
Q4 25
$76.4M
Q3 25
$83.3M
Q2 25
$71.0M
$79.2M
Q1 25
$69.2M
Q4 24
$68.2M
Q3 24
$58.4M
Q2 24
$71.1M
$53.4M
Net Profit
CHR
CHR
PRCT
PRCT
Q1 26
$-31.6M
Q4 25
$-29.8M
Q3 25
$-21.4M
Q2 25
$7.8M
$-19.6M
Q1 25
$-24.7M
Q4 24
$-18.9M
Q3 24
$-21.0M
Q2 24
$12.4M
$-25.6M
Gross Margin
CHR
CHR
PRCT
PRCT
Q1 26
64.9%
Q4 25
60.6%
Q3 25
64.8%
Q2 25
70.7%
65.4%
Q1 25
63.9%
Q4 24
64.0%
Q3 24
63.2%
Q2 24
73.4%
59.0%
Operating Margin
CHR
CHR
PRCT
PRCT
Q1 26
-4.1%
Q4 25
-40.6%
Q3 25
-27.8%
Q2 25
11.7%
-28.0%
Q1 25
-39.7%
Q4 24
-28.9%
Q3 24
-38.4%
Q2 24
16.4%
-50.3%
Net Margin
CHR
CHR
PRCT
PRCT
Q1 26
-38.1%
Q4 25
-39.1%
Q3 25
-25.7%
Q2 25
10.9%
-24.7%
Q1 25
-35.8%
Q4 24
-27.6%
Q3 24
-35.9%
Q2 24
17.5%
-48.0%
EPS (diluted)
CHR
CHR
PRCT
PRCT
Q1 26
$-0.56
Q4 25
$-0.54
Q3 25
$-0.38
Q2 25
$0.67
$-0.35
Q1 25
$-0.45
Q4 24
$-0.34
Q3 24
$-0.40
Q2 24
$1.23
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CHR
CHR
PRCT
PRCT
Cash + ST InvestmentsLiquidity on hand
$245.6M
Total DebtLower is stronger
$51.7M
Stockholders' EquityBook value
$322.1M
$347.7M
Total Assets
$362.7M
$487.1M
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CHR
CHR
PRCT
PRCT
Q1 26
$245.6M
Q4 25
$286.5M
Q3 25
$294.3M
Q2 25
$302.7M
Q1 25
$316.2M
Q4 24
$333.7M
Q3 24
$196.8M
Q2 24
$186.1M
$214.1M
Total Debt
CHR
CHR
PRCT
PRCT
Q1 26
$51.7M
Q4 25
$51.6M
Q3 25
$51.6M
Q2 25
$51.5M
Q1 25
$51.5M
Q4 24
$51.5M
Q3 24
$51.4M
Q2 24
$51.4M
Stockholders' Equity
CHR
CHR
PRCT
PRCT
Q1 26
$347.7M
Q4 25
$365.9M
Q3 25
$380.3M
Q2 25
$322.1M
$385.8M
Q1 25
$389.2M
Q4 24
$402.2M
Q3 24
$241.2M
Q2 24
$286.1M
$251.8M
Total Assets
CHR
CHR
PRCT
PRCT
Q1 26
$487.1M
Q4 25
$508.1M
Q3 25
$511.5M
Q2 25
$362.7M
$513.1M
Q1 25
$519.4M
Q4 24
$534.0M
Q3 24
$374.1M
Q2 24
$333.2M
$374.4M
Debt / Equity
CHR
CHR
PRCT
PRCT
Q1 26
0.15×
Q4 25
0.14×
Q3 25
0.14×
Q2 25
0.13×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.21×
Q2 24
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CHR
CHR
PRCT
PRCT
Operating Cash FlowLast quarter
$3.9M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
0.51×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CHR
CHR
PRCT
PRCT
Q1 26
Q4 25
$-10.3M
Q3 25
$-6.6M
Q2 25
$3.9M
$-15.0M
Q1 25
$-17.0M
Q4 24
$-32.4M
Q3 24
$-18.8M
Q2 24
$-6.7M
$-15.7M
Free Cash Flow
CHR
CHR
PRCT
PRCT
Q1 26
Q4 25
$-12.2M
Q3 25
$-9.5M
Q2 25
$-17.8M
Q1 25
$-18.8M
Q4 24
$-33.6M
Q3 24
$-19.0M
Q2 24
$-16.8M
FCF Margin
CHR
CHR
PRCT
PRCT
Q1 26
Q4 25
-15.9%
Q3 25
-11.4%
Q2 25
-22.5%
Q1 25
-27.2%
Q4 24
-49.2%
Q3 24
-32.6%
Q2 24
-31.4%
Capex Intensity
CHR
CHR
PRCT
PRCT
Q1 26
Q4 25
2.4%
Q3 25
3.4%
Q2 25
3.5%
Q1 25
2.7%
Q4 24
1.7%
Q3 24
0.4%
Q2 24
2.0%
Cash Conversion
CHR
CHR
PRCT
PRCT
Q1 26
Q4 25
Q3 25
Q2 25
0.51×
Q1 25
Q4 24
Q3 24
Q2 24
-0.54×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CHR
CHR

Segment breakdown not available.

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

Related Comparisons